Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018124619) METHOD FOR DIAGNOSING BLADDER CANCER VIA MICROBIAL METAGENOMIC ANALYSIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/124619 International Application No.: PCT/KR2017/015177
Publication Date: 05.07.2018 International Filing Date: 21.12.2017
IPC:
C12Q 1/68 (2006.01)
[IPC code unknown for C12Q 1/68]
Applicants:
주식회사 엠디헬스케어 MD HEALTHCARE INC. [KR/KR]; 서울시 마포구 월드컵북로56길 9, 1303호 (상암동, 우리기술빌딩) (Sangam-dong,Woori Technology Bldg.) #1303, 9, World Cup buk-ro 56-gil, Mapo-gu, Seoul 03923, KR
Inventors:
김윤근 KIM, Yoon-Keun; KR
Agent:
이명진 LEE, Myoung-Jin; KR
Priority Data:
10-2016-017924026.12.2016KR
10-2017-017582220.12.2017KR
Title (EN) METHOD FOR DIAGNOSING BLADDER CANCER VIA MICROBIAL METAGENOMIC ANALYSIS
(FR) PROCÉDÉ DE DIAGNOSTIC DU CANCER DE LA VESSIE PAR ANALYSE MÉTAGÉNOMIQUE MICROBIENNE
(KO) 미생물 메타게놈 분석을 통한 방광암 진단방법
Abstract:
(EN) The present invention relates to a method for diagnosing bladder cancer via microbial metagenomic analysis and, more particularly, to a method for diagnosing bladder cancer by performing metagenomic analysis of a microbe, such as a bacterium and an archaeon, by using a subject-derived sample, and analyzing an increase or decrease in the content of a specific microbe-derived extracellular vesicle. An extracellular vesicle secreted from a microbe, such as a bacterium, present in the environment can be absorbed into the body and directly affect the occurrence of cancer, and bladder cancer is difficult to diagnose early on before any symptom appears, which makes efficient treatment difficult. As such, through the metagenomic analysis of a microbe, such as a bacterium and an archaeon, using a human body-derived sample according to the present invention, the risk of the onset of bladder cancer can be predicted in advance, enabling early diagnosis and prediction of a bladder cancer risk group and delay of the time of the onset or prevention of the onset with proper care, and early diagnosis is still possible even after the onset, which can lower the incidence rate of bladder cancer and enhance the treatment effect.
(FR) La présente invention concerne un procédé de diagnostic du cancer de la vessie par analyse métagénomique microbienne et, plus particulièrement, un procédé de diagnostic du cancer de la vessie par la réalisation d'une analyse métagénomique d'un microbe, tel qu'une bactérie et une archée, à l'aide d'un échantillon dérivé d'un sujet et par l'analyse d'une augmentation ou d'une diminution de la teneur en une vésicule extracellulaire dérivée d'un microbe spécifique. Une vésicule extracellulaire sécrétée par un microbe, tel qu'une bactérie, présente dans l'environnement peut être absorbée dans le corps et influencer directement l'apparition d'un cancer et le diagnostic précoce d'un cancer de la vessie est difficile avant l'apparition d'un quelconque symptôme, ce qui complique un traitement efficace. Ainsi, par l'intermédiaire de l'analyse métagénomique d'un microbe, tel qu'une bactérie et une archée, à l'aide d'un échantillon dérivé du corps humain selon la présente invention, le risque d'apparition d'un cancer de la vessie peut être prédit à l'avance, ce qui permet un diagnostic précoce et la prédiction d'un groupe à risque du cancer de la vessie et de retarder le moment d'apparition ou de prévenir l'apparition par des soins appropriés et un diagnostic précoce est encore possible même après l'apparition, ce qui peut abaisser le taux d'incidence du cancer de la vessie et améliorer l'effet de traitement.
(KO) 본 발명은 미생물 메타게놈 분석을 통해 방광암을 진단하는 방법에 관한 것으로서, 보다 구체적으로는 피검체 유래 샘플을 이용해 세균 및 고세균 등의 미생물 메타게놈 분석을 수행하여 특정 미생물 유래 세포밖 소포의 함량 증감을 분석함으로써 방광암을 진단하는 방법에 관한 것이다. 환경에 존재하는 세균 등의 미생물에서 분비되는 세포밖 소포는 체내에 흡수되어 암 발생에 직접적인 영향을 미칠 수 있으며, 방광암은 증상이 나타나기 전 조기진단이 어려워 효율적인 치료가 어려운 실정이므로, 본 발명에 따른 인체 유래 샘플을 이용한 세균 및 고세균 등의 미생물 메타게놈 분석을 통해 방광암 발병의 위험도를 미리 예측함으로써 방광암의 위험군을 조기에 진단 및 예측하여 적절한 관리를 통해 발병 시기를 늦추거나 발병을 예방할 수 있으며, 발병 후에도 조기진단 할 수 있어 방광암의 발병률을 낮추고 치료효과를 높일 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)